1Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours[J]. Eur Respir J, 2001,18:1059-1068.
2Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors [J]. Semin in Roentgenol, 2005,40(2) : 90-97.
3Kris MG, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase Ⅱ trial in patients with bronchioloalveolar cacinoma (BAC) [J].Proc Am Soc Clin Oncol, 2004,23:631S.
4Jackman DM, Chirieac LR, Janne PA. Bronchioloalveolar carcinoma: A review of the epidemiology, pathology, and treatment [J]. Semin Respir Crit Care Med, 2005,26 (3):342-352.
5Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma [J ]. Ann Thorac Surg, 2002,74(5) : 1640-1646.
6Furak J, Trojan I, Szoke T, et al. Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival [J]. Eur Cardiothorac Surg, 2003,23 : 818-823.
7Roberts PF, Straznicka M, Lara PN, et al. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved [J]. J Thorac Cardiovasc Surg, 2003,126: 1597-1601.
8West HL, Crowley J J, Vance RB, et al. Advanced brocnhioloalveolar carcinoma: A phase Ⅱ trial of paclitaxel by 96-hour infusion (SWOG 9714) [J]. Ann Oncol : in press.
9West H, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126 [J]. J Clin Oncol, 2006,24(12):1807-1813.
10Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers [J]. Clin Cancer Res, 2005,11 (8) :3032-3037.
1ltigashiyama M, Kodama K, Yokouchi H, et al. Prognostic val- ue of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma[ J]. Ann Thorac Surg, 1999,68:2069-2073.
2Rena O, Papalia E, Ruffini E, et al. Stage I pure bronchioloal- veolar carcinoma:recurrences, survival and comparison with adenocarcinoma of the lung[ J]. Eur J Cardiothorac Surg,2003,23 : 409-414.
3Travis WD, Colby TV, Coffin B, et al. Histological typing of lung and pleural tumors. World Health Organization international histological classification of tumors [ M ]. 3rd ed. Berlin: Springer, 1999.
4Asamura H, Suzuki K, Watanabe S, et al. A clinicopathological study of resected sub-centimeter lung cancers: a favorable progno- sis for ground glass opacity lesions[J]. Ann Thorac Surg, 2003, 76 : 1016-1022.
5Breathnach OS, Kwiatkowski D J, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease [ J ]. J Thorac Cardiovasc Surg, 2001,121:42.-47.
6Barlesi F, Doddoli C, Gimenez C, et al. Bronehioloalveolar carcinoma:myths and realities in the surgical management[J]. Eur J Cardiothorac Surg, 2003 ,24:159-164.
7Yamato Y, Tsuehida M, Watanabe T, et al. Early results of a prospective study of limited resection for brenchioloalveolar adenocarcinoma of the lung[J]. Ann Thorac Surg, 2001,71:971- 974.
8Sawabata N, Ohta M, Matsumura A, et al. Optimal distance of malignant negative margin in excision of non-small cell lung cancer: a multicenter prospective study [ J]. Ann Thorac Surg, 2004, 77:415-420.
9Goo J, Kyung W, Park, et al. Clinical, pathological and thin- section CT feature of persistent ground - glass pacity nodule. Lung Cancer 2009,64(2) : 171.
10Onkoh T, Nagareda T, Sekiguchi J, et al. Detectability of perperipheral lung cancer on pulmonary ad with ground- glass atten tion on thin - section ct: quantification by three - dimensional image analzing method. European journal of radiology,2008,65( 1 ) : 104.
